Category: 17228-38-5

Adding a certain compound to certain chemical reactions, such as: 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, belongs to imidazoles-derivatives compound, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound 17228-38-5, name: N-Methyl-1H-benzo[d]imidazol-2-amine

(5R,8aS)-3-Chloro-1 -(1 -methanesulfonyl-1 -methyl-ethyl)-5-methyl-5,6,8a,9- tetrahydro-8H-7,1 0-dioxa-2,4,4b-triaza-phenanthrene (1 .85 g), benzimidazole2-yl-methylamine (719 mg), tris(dibenzylideneacetone)dipalladium(0) (895 mg; 0.2 eq.) and dicyclohexyl-(2?,4?,6?-triisopropyl-biphenyl-2-yl)-phosphane (932 mg) were dissolved in dioxane (10 ml), lithium tert-butoxide (1,0 M solution in tetrahydrofuran) (6.8 ml, 1.4 eq) was added and the mixture was stirred for 1 h at 80 00. The reaction mixture was purified by chromatography(dichloromethane I methanol) to afford {1 -[(5R,8aS)-1 -(1 -Methanesulfonyl-1 -methyl-ethyl )-5-methyl -5,6 ,8a ,9-tetrahyd ro-8 H-7, 1 0-d ioxa-2 ,4 ,4b-triaza-phenanthren-3-yl]-1 H-benzimidazol-2-yl}-methyl-amine as a yellow solid (1 .18g); LCMS (method E): 0.50 mm (purity 98%); [MH+] 473.3 mlz; 1H NMR (500MHz, DMSO-d6) 6 8.19 (q, J = 4.8 Hz, 1 H), 8.00 (d, J = 7.6 Hz, 1 H), 7.28 -7.21 (m, 1 H), 7.07 (td, J = 7.6, 1 .2 Hz, 1 H), 6.97 (td, J = 7.7, 1 .3 Hz, 1 H), 4.63 (qd, J = 6.8, 2.9 Hz, 1 H), 4.43 (dd, J = 11 .0, 3.4 Hz, 1 H), 4.04 – 3.94 (m, 2H),3.88 (d, J= 11.6 Hz, 1H), 3.83 (dd, J= 11.1,9.2Hz, 1H), 3.70 (dd, J 11.6,3.2 Hz, 1 H), 3.22 -3.15 (m, 1 H), 3.05-3.01 (m, 6H), 1.84 (5, 3H), 1.81(s, 3H), 1 .35 (d, J = 6.8 Hz, 3H)and (1 H-Benzimidazol-2-yl)-[(5R,8aS)-1 -(1 -methanesulfonyl-1 -methyl-ethyl)-5- methyl-5,6,8a,9-tetrahydro-8H-7, 1 0-dioxa-2,4,4b-triaza-phenanthren-3-yl]-methyl-amine as a beige solid (722 mg); LCMS (method E): 0.53 mm (purity94%);[MH+]473.3m/z; 1H NMR (400 MHz, DMSO-d6)o 12.40(s, 1H),7.45-7.38 (m, 1 H), 7.34 – 7.27 (m, 1 H), 7.11 – 7.00 (m, 2H), 4.67 (qd, J = 6.5, 2.7Hz, 1 H), 4.38 (dd, J = 11 .0, 3.5 Hz, 1 H), 3.99 – 3.89 (m, 2H), 3.82 (d, J = 11.5Hz, 1 H), 3.76 (dd, J = 11 .0, 8.8 Hz, 1 H), 3.72 (s, 3H), 3.65 (dd, J = 11.7, 3.3 Hz, 1H), 3.15 (t, J= 11.8 Hz, 1H), 3.04 (s, 3H), 1.83 (s, 3H), 1.81 (s, 3H), 1.29(d, J = 6.8 Hz, 3H).

At the same time, in my other blogs, there are other synthetic methods of this type of compound, N-Methyl-1H-benzo[d]imidazol-2-amine, and friends who are interested can also refer to it.

Reference:
Patent; MERCK PATENT GMBH; BURGDORF, Lars; DORSCH, Dieter; TSAKLAKIDIS, Christos; (189 pag.)WO2017/202748; (2017); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Related Products of 17228-38-5, A common heterocyclic compound, 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, molecular formula is C8H9N3, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

To a suspension of intermediate 2-XI (70mg, 0.173 mmol) in ACN (1.5 mL) and DMF (0.15 mL) was added A/-methyl-1 /-/-1 ,3-benzodiazol-2-amine (51 mg, 0.347 mmol) and Cs2C03 (282 mg, 0.867 mmol). The reaction mixture was heated in a sealed tube at 130C for 40 hours. On cooling, H20 (50 mL) and EtOAc (40 mL) were added. A solid appeared in the interphase, it was filtered and washed with EtOAc and Et20 to give final product 32 as a white solid (35 mg). LC-MS1 , tR= 3.98 min, MS: 515.2 [M+H]+ 1 H NMR (300 MHz, DMSO) delta 7.97 (d, J = 7.6 Hz, 1 H), 7.88 (q, J = 4.9 Hz, 1 H), 7.25 (d, J = 7.3 Hz, 1 H), 7.07 (t, J = 7.1 Hz, 1 H), 6.98 (t, J = 7.6 Hz, 1 H), 4.43 – 4.29 (m, 1 H), 4.24 (m, 1 H), 4.10 – 3.76 (m, 8H), 3.56 (m, 1 H), 3.46 – 3.36 (m, 2H), 3.03 (m, 1 H), 2.99 (d, J=4.9Hz, 3H), 2.94 (s, 3H), 2.89 (m, 1 H), 2.30 – 1.96 (m, 4H).

The synthetic route of 17228-38-5 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III; PASTOR FERNANDEZ, Joaquin; FERNANDEZ-CAPETILLO RUIZ, Oscar; MARTINEZ GONZALEZ, Sonia; BLANCO APARICIO, Carmen; RICO FERREIRA, Maria del Rosario; TOLEDO LAZARO, Luis Ignacio; RODRIGUEZ ARISTEGUI, Sonsoles; MURGA COSTA, Matilde; VARELA BUSTO, Carmen; LOPEZ CONTRERAS, Andres Joaquin; RENNER, Oliver; NIETO SOLER, Maria; CEBRIAN MUNOZ, David Alvaro; WO2014/140644; (2014); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

In the chemical reaction process, reaction time, type of solvent, can easily affect the result of the reaction, thereby determining the yield and properties of the reaction product. An updated downstream synthesis route of 17228-38-5 as follows. Safety of N-Methyl-1H-benzo[d]imidazol-2-amine

Example 2.03 can also be prepared as follows:(3R)-4-(2-Chloro-6-(1-((R)-S-methylsulfonimidoyl)cyclopropyl)pyrimidin-4-yl)-3-methylmorpholine (179 mg, 0.54 mmol), N-methyl-1H-benzo[d]imidazol-2-amine (159 mg, 1.08 mmol) and cesium carbonate (529 mg, 1.62 mmol) were suspended in DMA (2 ml) and sealed into a microwave tube. The reaction mixture was heated to 80 C. for 90 minutes in a microwave reactor and then cooled to RT. The reaction mixture was filtered and then purified by preparative HPLC, using decreasingly polar mixtures of water (containing 1% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to afford a solid (55.0 mg). In an additional procedure: (R)-4-(2-Chloro-6-(1-((R)-S-methylsulfonimidoyl)cyclopropyl)pyrimidin-4-yl)-3-methylmorpholine (89 mg, 0.27 mmol), N-methyl-1H-benzo[d]imidazol-2-amine (79 mg, 0.54 mmol) and cesium carbonate (263 mg, 0.81 mmol) were suspended in DMA (2 ml) and sealed into a microwave tube. The reaction mixture was heated to 80 C. for 5 hours in a microwave reactor and then cooled to RT. The reaction mixture was filtered, and combined with the solid from the previous procedure and then purified by preparative HPLC using decreasingly polar mixtures of water (containing 1% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated and the residue was purified by preparative HPLC using decreasingly polar mixtures of water (containing 0.1% formic acid) and MeCN as eluents. Fractions containing the desired compound were evaporated and the residue purified again by preparative HPLC using decreasingly polar mixtures of water (containing 1% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to afford the title compound (38.4 mg, 32%); 1H NMR (400 MHz, DMSO-d6) 1.29 (3H, d), 1.52 (3H, m), 1.72-1.86 (1H, m), 3.02 (3H, s), 3.03 (3H, d), 3.26-3.33 (1H, m), 3.52 (1H, t), 3.66 (1H, d), 3.80 (1H, d), 4.01 (2H, m), 4.12 (1H, s, obscured by methanol peak), 4.51 (1H, s), 6.77 (1H, s), 6.98 (1H, t), 7.09 (1H, t), 7.25 (1H, d), 8.08 (1H, d), 8.71 (1H, d); m/z: (ES+) MH+, 442.16. Chiral HPLC: (HP1100 System 4, 20 mum Chiralpak AS (250 mm×4.6 mm) column eluting with iso-Hexane/IPA/TEA 70/30/0.1) Rf, 11.984 97.9%.

According to the analysis of related databases, 17228-38-5, the application of this compound in the production field has become more and more popular.

Reference:
Patent; ASTRAZENECA AB; US2011/306613; (2011); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Researchers who often do experiments know that organic synthesis is a process of preparing more complex target molecules from simple raw materials through one or more chemical reactions. Generally, it requires fewer steps, and cheap raw materials. 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, A new synthetic method of this compound is introduced below., Product Details of 17228-38-5

To a solution of N-methyl-1H-benzimidazol-2-amine (1.36 g, 9.24 mmol, 1.00) in acetonitrile (40 mL) was added cesium carbonate (12 g, 37.0 mmol, 4 equiv) followed by methyl 4-bromobutanoate (1.40 mL, 2.01 g, 11.1 mmol, 1.0 equiv). The reaction mixture was stirred overnight at RT, then was filtered through Celite and concentrated to dryness in vacuo. The residue was purified by flash column chromatography (silica gel, 100-200 mesh, 0 to 10% methanol in dichloromethane) to afford methyl 4-[2-(methylamino)benzimidazol-1-yl]butanoate (0.65 g, 28%) as an orange oil. LCMS (5 to 95% acetonitrile in water + 0.1% formic acid over 2 mins) retention time 0.88 min, ESI+ found [M+H]

The basis of chemical reaction formula synthesis, the synthesis route is composed of some specific reactions and combined according to certain logical thinking. We look forward to the emergence of more reaction modes in the future.

Reference:
Patent; GENENTECH, INC.; F. HOFFMANN-LA ROCHE AG; PATEL, Snahel; HAMILTON, Gregory; STIVALA, Craig; CHEN, Huifen; ZHAO, Guiling; (1236 pag.)WO2017/4500; (2017); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Application of 17228-38-5, Each compound has different characteristics, and only by selecting the characteristics of the compound suitable for a specific situation can the compound be applied on a large scale. 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, This compound has unique chemical properties. The synthetic route is as follows.

2-((5R,8aS)-3-Chloro-5-methyl-5,6,8a,9-tetrahydro-8H-7, 1 0-dioxa-2,4,4b-triaza-phenanthren-1 -yl)-propan-2-ol (154,51 mg; 0,500 mmol; 100,00 mol%), (1H-benzimidazol-2-yl)-methyl-amine (73,59 mg; 0,500 mmol; 100,00 mol%), tris(dibenzylideneacetone)dipalladium(0) (91,57 mg; 0,100 mmol; 20,00 mol%) and dicyclohexyl-(2?,4?,6?-triisopropyl-biphenyl-2-yl)-phosphane (95,34 mg; 0,200 mmol; 40,00 mol%) were dissolved in dioxane (1,36 ml; 15,845 mmol;31 69,00 mol%), lithium tert-butoxide (1,0 M solution in tetrahydrofuran)(700,00 p1; 0,700 mmol; 140,00 mol%) was added and the mixture was stirredfor 1 h at 80 00. The reaction mixture was purified by column chromatography(petroleum benzene I ethyl acetate) to afford the product as yellow solid(14.8mg, 6.5%); LCMS (method C): 1 .29 mm (purity 89.6%); [MH+] 411 .3 mlz;1H NMR (400 MHz, DMSO-d6)o 13.08 (5, 1H), 7.42 (d, J 7.1 Hz, 1H), 7.37-7.23 (m, 1 H), 7.16-7.00 (m, 2H), 5.37 (5, 1 H), 4.69-4.57 (m, 1 H), 4.35 (dd,J = 10.9, 3.2 Hz, 1 H), 3.97 – 3.84 (m, 2H), 3.81 (d, J = 11 .5 Hz, 1 H), 3.74 -3.71 (m, 1 H), 3.65 (dd, J = 11 .6, 3.3 Hz, 1 H), 3.29 (5, 3H), 3.23 – 3.09 (m, 1 H),1 .52 (5, 3H), 1 .51 (5, 3H), 1 .27 (d, J = 6.8 Hz, 3H).

The chemical industry reduces the impact on the environment during synthesis N-Methyl-1H-benzo[d]imidazol-2-amine. I believe this compound will play a more active role in future production and life.

Reference:
Patent; MERCK PATENT GMBH; BURGDORF, Lars; DORSCH, Dieter; TSAKLAKIDIS, Christos; (189 pag.)WO2017/202748; (2017); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Synthetic Route of 17228-38-5, These common heterocyclic compound, 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

EXAMPLE 2.03 AND EXAMPLE 2.04 N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-benzimidazol-2-amine and N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((S)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-benzimidazol-2-amine; Cesium carbonate (942 mg, 2.89 mmol) was added to (3R)-4-(2-chloro-6-(1-(S-methylsulfonimidoyl)cyclopropyl)pyrimidin-4-yl)-3-methylmorpholine (319 mg, 0.96 mmol) and N-methyl-1H-benzo[d]imidazol-2-amine (284 mg, 1.93 mmol) in DMA (10 ml). The resulting suspension was stirred at 80 C. for 45 hours. A further portion of N-methyl-1H-benzo[d]imidazol-2-amine (284 mg, 1.93 mmol), cesium carbonate (942 mg, 2.89 mmol) and sodium methanesulfinate (98 mg, 0.96 mmol) were added and the suspension was stirred at 80 C. for 70 hours. The reaction mixture was filtered and then evaporated. The residue was dissolved in EtOAc (250 ml), and washed sequentially with water (250 ml) and saturated brine (75 ml). The organic layer was dried over MgSO4, filtered and evaporated onto silica gel (5 g). The resulting powder was purified by flash chromatography on silica, eluting with a gradient of 0 to 5% MeOH in DCM. Pure fractions were evaporated and the residue was purified by preparative chiral chromatography on a Merck 50 mm, 20 mum Chiralpak AS column, eluting isocratically with 70% isohexane in IPA (modified with Et3N) as eluent. The fractions containing the desired compound were evaporated to afford the title compound: N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-benzimidazol-2-amine (166 mg, 39%) as the first eluting compound; 1H NMR (400 MHz, DMSO-d6) 1.29 (3H, d), 1.47 (2H, dq), 1.55-1.66 (1H, m), 1.69-1.89 (1H, m), 3.01 (3H, s), 3.04 (3H, d), 3.30-3.39 (1H, m), 3.52 (1H, td), 3.66 (1H, dd), 3.80 (1H, d), 3.95 (1H, s), 4.01 (1H, dd), 4.09 (1H, d), 4.51 (1H, s), 6.77 (1H, s), 6.97 (1H, t), 7.08 (1H, t), 7.25 (1H, d), 8.08 (1H, d), 8.67 (1H, d); m/z: (ES+) MH-, 442.09. Chiral HPLC: (HP1100 System 4, 20 mum Chiralpak AS (250 mm×4.6 mm) column eluting with iso-Hexane/IPA/TEA 70/30/0.1) Rf, 12.219 >99%.and the title compound: N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((S)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-benzimidazol-2-amine (123 mg, 29%) as the second eluting compound; 1H NMR (400 MHz, DMSO-d6) 1.33 (3H, t), 1.45-1.61 (2H, m), 1.61-1.68 (1H, m), 1.80-1.89 (1H, m), 3.07 (3H, s), 3.09 (3H, d), 3.39 (1H, dd), 3.58 (1H, td), 3.72 (1H, dd), 3.86 (1H, d), 4.01 (1H, s), 4.06 (1H, dd), 4.15 (1H, d), 4.55 (1H, s), 6.82 (1H, s), 7.03 (1H, t), 7.14 (1H, t), 7.31 (1H, d), 8.14 (1H, d), 8.73 (1H, d); m/z: (ES+) MH+, 442.09. Chiral HPLC: (HP1100 System 4, 20 mum Chiralpak AS (250 mm×4.6 mm) column eluting with iso-Hexane/IPA/TEA 70/30/0.1) Rf, 25.093 >99%.

Statistics shows that N-Methyl-1H-benzo[d]imidazol-2-amine is playing an increasingly important role. we look forward to future research findings about 17228-38-5.

17228-38-5, These common heterocyclic compound, 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

A mixture of 5- (6-formyl-pyridin-2-yl)-thiophene-2-carboxylic acid [88mg, 0. [38MMOL,] Reference Example 14 (e)], [(LH-BENZOIMIDAZOL-2-YL)-METHYLAMINE] (60mg, 0.38mmol) and anhydrous ethanol (4ml) was stirred at room temperature for 2 hours, before sodium borohydride (30mg, 0.76mmol) was added. After stirring overnight the reaction mixture was concentrated, to provide 5-(6-{[(1H-benzoimidazol-2-ylmethyl)-amino]-methyl}- [PYRIDIN-2-YL)-THIOPHENE-2-CARBOXYLIC] acid as an off-white solid, which was used directly without further purification. LCMS (Method C): [RT] = 1.89 minutes; 365 (M+H) +.

Chemical properties determine the actual use. Each compound has specific chemical properties and uses. We look forward to more synthetic routes in the future to expand reaction routes of 17228-38-5.

Reference:
Patent; ARGENTA DISCOVERY LIMITED; WO2004/13130; (2004); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Adding some certain compound to certain chemical reactions, such as: 17228-38-5, name is N-Methyl-1H-benzo[d]imidazol-2-amine, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound 17228-38-5. 17228-38-5

EXAMPLE 4.01 AND EXAMPLE 4.02 N-Methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[4-((S)-S-methylsulfonimidoyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-benzimidazol-2-amine and N-methyl-1-{4-[(3R)-3-methylmorpholin-4-yl]-6-[4-((R)-S-methylsulfonimidoyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-benzimidazol-2-amine; Cesium carbonate (2.076 g, 6.37 mmol) was added to N-[(4-{2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl}tetrahydro-2H-pyran-4-yl)(methyl)oxido-lambda6-sulfanylidene]-2,2,2-trifluoroacetamide (1.00 g, 2.12 mmol), sodium methanesulfinate (0.217 g, 2.12 mmol) and N-methyl-1H-benzo[d]imidazol-2-amine (0.313 g, 2.12 mmol) in DMA (20 ml). The resulting suspension was stirred at 80 C. for 18 hours. The reaction mixture was filtered and then evaporated. The residue was dissolved in EtOAc (100 mL) and washed sequentially with water (100 mL) and then with saturated brine (10 mL). The aqueous layer was washed with EtOAc (2¡Á100 mL). The organic layers were combined, dried over MgSO4, filtered and then evaporated. The residue was purified by flash chromatography on silica, eluting with a gradient of 0 to 7% MeOH in DCM. Fractions containing product were evaporated and the residue was purified by preparative chiral HPLC on a ChiralCel OD column, eluting isocratically with 50% hexane in EtOH (modified with Et3N) as eluent. Fractions containing isomer 1, eluted first, were evaporated and the residue dissolved in DCM (10 ml) and then evaporated onto silica (0.5 g). The resulting powder was purified by flash chromatography on silica, eluting with a gradient of 0 to 7% MeOH in DCM. Pure fractions were evaporated to dryness to afford isomer 1 (58.0 mg, 36%); 1H NMR (400 MHz, DMSO-d6) 1.31 (3H, d), 2.19-2.35 (2H, m), 2.65-2.75 (5H, m), 3.02 (2H, d), 3.24 (2H, dd), 3.33-3.39 (1H, m), 3.56 (1H, td), 3.71 (1H, dd), 3.81 (1H, d), 3.87-3.97 (2H, m), 4.03 (1H, dd), 4.06 (1H, s), 4.16 (1H, d), 4.53 (1H, s), 6.90 (1H, s), 6.99 (1H, td), 7.09 (1H, td), 7.26 (1H, dd), 8.06 (1H, d), 8.39 (1H, q); m/z: (ES+) MH-, 486.53. Chiral HPLC: (HP1100 System 4, 20 mum Chiralpak OJ (250 mm¡Á4.6 mm) column eluting with Hexane/EtOH/TEA 50/50/0.1) Rf, 8.874 >99%.Fractions containing isomer 2, eluted second, were evaporated and the residue dissolved in DCM (10 mL) and then evaporated onto silica gel (0.5 g). The resulting powder was purified by flash chromatography on silica, eluting with a gradient of 0 to 7% MeOH in DCM. Pure fractions were evaporated to afford isomer 2 (71.8 mg, 44%); 1H NMR (400 MHz, DMSO-d6) 1.30 (3H, d), 2.19-2.36 (2H, m), 2.61-2.76 (5H, m), 3.02 (3H, d), 3.18-3.27 (2H, m), 3.36 (1H, dd), 3.56 (1H, td), 3.71 (1H, dd), 3.81 (1H, d), 3.93 (2H, dd), 4.00-4.08 (2H, m), 4.17 (1H, d), 4.52 (1H, s), 6.91 (1H, s), 6.99 (1H, td), 7.09 (1H, td), 7.26 (1H, d), 8.06 (1H, d), 8.39 (1H, q); m/z: (ES+) MH+, 486.57. Chiral HPLC: (HP1100 System 4, 20 mum Chiralpak OJ (250 mm¡Á4.6 mm) column eluting with Hexane/EtOH/TEA 50/50/0.1) Rf, 12.742 >99%.

Chemical properties determine the actual use. Each compound has specific chemical properties and uses. We look forward to more synthetic routes in the future to expand reaction routes of N-Methyl-1H-benzo[d]imidazol-2-amine.

Reference:
Patent; ASTRAZENECA AB; US2011/306613; (2011); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem